2.Outcomes of Surgical and Endovascular Treatment for Cephalic Arch Stenosis in Proximal Arteriovenous Fistula
Young Ryul PARK ; Ji Hyun JUNG ; Deokbi HWANG ; Woo-Sung YUN ; Seung HUH ; Hyung-Kee KIM
Vascular Specialist International 2024;40(2):13-
Purpose:
The cephalic arch is a significant site of stenosis in proximal arteriovenous fistulas (AVFs) that contributes to access dysfunction and thrombosis. This study aimed to evaluate the outcomes of surgical treatment (ST) and endovascular treatment (ET) for cephalic arch stenosis (CAS).
Materials and Methods:
A total of 62 patients with proximal AVF who underwent CAS revision using either ST or ET were enrolled between January 2018 and March 2023. In the ET group, only the initial ET following AVF formation was considered, to mitigate bias. In the ST group, central transposition of the native AVF (transposition group) or interposition of the prosthetic graft into the proximal basilic or axillary vein (interposition group) was performed. We evaluated primary and functional patency based on these groups and calculated the number of patency loss events after CAS treatment.
Results:
Of the 62 patients, 38 (61%) were male, with a mean age of 66.4 years. ST was performed in 26 (42%) patients, including transposition in 16 and interposition in 10, whereas ET was administered to 36 patients during the study period.Among the ST recipients, 42% had a history of ET for CAS. The incidence of AVF thrombosis was marginally higher in the ST group than in the ET group (39% vs.19%, P=0.098). The primary patency rates at 6 months, 1 year, and 3 years were 87%, 87%, and 66% in the transposition group; 45%, 23%, and 11% in the interposition group; and 66%, 49%, and 17% in the ET group, respectively. Notably, the primary patency of the transposition group was significantly higher than that of the interposition (P=0.001) and ET groups (P=0.016). The frequency of patency loss events per person-year after the initial revision was 0.40, 0.52, and 1.42 in the transposition, interposition, and ET groups, respectively.
Conclusion
Transposition exhibited the most favorable primary patency rate and the lowest number of subsequent patency loss events during follow-up despite the higher rates of AVF thrombosis and previous ET at presentation. Consequently, transposition should be actively considered in eligible patients with CAS.
3.6-Shogaol, an Active Ingredient of Ginger, Improves Intestinal and Brain Abnormalities in Proteus Mirabilis-Induced Parkinson’s Disease Mouse Model
Eugene HUH ; Jin Gyu CHOI ; Yujin CHOI ; In Gyoung JU ; Dongjin NOH ; Dong-yun SHIN ; Dong Hyun KIM ; Hi-Joon PARK ; Myung Sook OH
Biomolecules & Therapeutics 2023;31(4):417-424
Parkinson’s disease (PD) which has various pathological mechanisms, recently, it is attracting attention to the mechanism via microbiome-gut-brain axis. 6-Shogaol, a representative compound of ginger, have been known for improving PD phenotypes by reducing neuroinflammatory responses. In the present study, we investigated whether 6-shogaol and ginger attenuate degeneration induced by Proteus Mirabilis(P. mirabilis) on the intestine and brain, simultaneously. C57BL/6J mice received P. mirabilis for 5 days. Ginger (300 mg/kg) and 6-shogaol (10 mg/kg) were treated by gavage feeding for 22 days including the period of P. mirabilis treatment. Results showed that 6-shogaol and ginger improved motor dysfunction and dopaminergic neuronal death induced by P. mirabilis treatment. In addition, they suppressed P. mirabilis-induced intestinal barrier disruption, pro-inflammatory signals such as toll-like receptor and TNF-α, and intestinal α-synuclein aggregation. Moreover, ginger and 6-shogaol significantly inhibited neuroinflammation and α-synuclein in the brain. Taken together, 6-shogaol and ginger have the potential to ameliorate PD-like motor behavior and degeneration of dopaminergic neurons induced by P. mirabilis in mice. Here, these findings are meaningful in that they provide the first experimental evidence that 6-shogaol might attenuate PD via regulating gut-brain axis.
4.Two Years of Experience and Methodology of Korean COVID-19 Living Clinical Practice Guideline Development
Miyoung CHOI ; Hyeon-Jeong LEE ; Su-Yeon YU ; Jimin KIM ; Jungeun PARK ; Seungeun RYOO ; Inho KIM ; Dong Ah PARK ; Young Kyung YOON ; Joon-Sung JOH ; Sunghoon PARK ; Ki Wook YUN ; Chi-Hoon CHOI ; Jae-Seok KIM ; Sue SHIN ; Hyun KIM ; Kyungmin HUH ; In-Seok JEONG ; Soo-Han CHOI ; Sung Ho HWANG ; Hyukmin LEE ; Dong Keon LEE ; Hwan Seok YONG ; Ho Kee YUM
Journal of Korean Medical Science 2023;38(23):e195-
Background:
In Korea, during the early phase of the coronavirus disease 2019 (COVID-19) pandemic, we responded to the uncertainty of treatments under various conditions, consistently playing catch up with the speed of evidence updates. Therefore, there was high demand for national-level evidence-based clinical practice guidelines for clinicians in a timely manner. We developed evidence-based and updated living recommendations for clinicians through a transparent development process and multidisciplinary expert collaboration.
Methods:
The National Evidence-based Healthcare Collaborating Agency (NECA) and the Korean Academy of Medical Sciences (KAMS) collaborated to develop trustworthy Korean living guidelines. The NECA-supported methodological sections and 8 professional medical societies of the KAMS worked with clinical experts, and 31 clinicians were involved annually. We developed a total of 35 clinical questions, including medications, respiratory/critical care, pediatric care, emergency care, diagnostic tests, and radiological examinations.
Results:
An evidence-based search for treatments began in March 2021 and monthly updates were performed. It was expanded to other areas, and the search interval was organized by a steering committee owing to priority changes. Evidence synthesis and recommendation review was performed by researchers, and living recommendations were updated within 3–4 months.
Conclusion
We provided timely recommendations on living schemes and disseminated them to the public, policymakers and various stakeholders using webpages and social media.Although the output was successful, there were some limitations. The rigor of development issues, urgent timelines for public dissemination, education for new developers, and spread of several new COVID-19 variants have worked as barriers. Therefore, we must prepare systematic processes and funding for future pandemics.
5.Comparison of fit and trueness of zirconia crowns fabricated by different combinations of open CAD-CAM systems
Eun-Bin BAE ; Won-Tak CHO ; Do-Hyun PARK ; Su-Hyun HWANG ; So-Hyoun LEE ; Mi-Jung YUN ; Chang-Mo JEONG ; Jung-Bo HUH
The Journal of Advanced Prosthodontics 2023;15(3):155-170
PURPOSE:
. This study aims to clinically compare the fitness and trueness of zirconia crowns fabricated by different combinations of open CAD-CAM systems.
MATERIALS AND METHODS:
. Total of 40 patients were enrolled in this study, and 9 different zirconia crowns were prepared per patient. Each crown was made through the cross-application of 3 different design software (EZIS VR, 3Shape Dental System, Exocad) with 3 different processing devices (Aegis HM, Trione Z, Motion 2). The marginal gap, absolute marginal discrepancy, internal gap(axial, line angle, occlusal) by a silicone replica technique were measured to compare the fit of the crown. The scanned inner and outer surfaces of the crowns were compared to CAD data using 3D metrology software to evaluate trueness.
RESULTS:
. There were significant differences in the marginal gap, absolute marginal discrepancy, axial and line angle internal gap among the groups (P < .05) in the comparison of fit. There was no statistically significant difference among the groups in terms of occlusal internal gap. The trueness ranged from 36.19 to 43.78 μm but there was no statistically significant difference within the groups (P > .05).
CONCLUSION
. All 9 groups showed clinically acceptable level of marginal gaps ranging from 74.26 to 112.20 μm in terms of fit comparison. In the comparison of trueness, no significant difference within each group was spotted. Within the limitation of this study, open CAD-CAM systems used in this study can be assembled properly to fabricate zirconia crown. [J Adv Prosthodont 2023;15:155-70]
6.Below-Knee Prosthetic Bypass Is a Viable Option for Limb Salvage in Patients with Extensive Femoropopliteal Occlusive Disease
Younghye KIM ; Ji Hyun JUNG ; Deokbi HWANG ; Woo-Sung YUN ; Seung HUH ; Hyung-Kee KIM
Vascular Specialist International 2023;39(2):16-
Purpose:
This study aimed to (1) evaluate the outcomes of below-knee prosthetic bypass (BKPB) in the absence of the great saphenous vein, and (2) identify risk factors associated with these outcomes.
Materials and Methods:
This study included 37 consecutive patients who underwent BKPB with or without distal modification between 2010 and 2022. We further assessed the following treatment outcomes: primary patency (PP), secondary patency (SP), limb salvage (LS), and amputation-free survival (AFS) rates. The risk factors for PP were also examined.
Results:
Most patients (n=31) were male. In 32 (86.5%) patients, BKPBs were performed for chronic limb-threatening ischemia. At the time of initial admission, two (5.4%) early deaths and three (8.1%) major amputations were noted. At 1 year after BKPB, the overall PP, SP, LS, and AFS rates were 78%, 85%, 85%, and 70%, respectively; at 3 years, they were 58%, 70%, 80%, and 52%, respectively; and at 5 years, they were 35%, 58%, 62%, and 29%, respectively. Notably, PP was significantly lower in limbs with ≤1 patent tibial arteries than in limbs with ≥2 patent artery (hazard ratio [HR], 3.80; 95% confidence interval [CI], 1.14-12.69 for overall; and HR, 12.97; 95% CI, 2.15-78.08 for distal anastomosis to below-knee popliteal artery). However, the PP was unaffected by the distal modification.
Conclusion
BKPB is a viable option for LS in patients with extensive femoropopliteal disease. Tibial runoff was significantly correlated with patency; therefore, decision-making for BKPB and follow-up must involve careful evaluation of the outflow arteries.
7.Evaluating the Safety and effectivenesS in adult KorEaN patients treated with Tolvaptan for management ofautosomal domInAnt poLycystic kidney disease (ESSENTIAL): short-term outcomes during the titration period
Hyuk HUH ; Yong Soo KIM ; Wookyung CHUNG ; Yong Lim KIM ; Yaerim KIM ; Seungyeup HAN ; Yeonsoon JUNG ; Ki Young NA ; Kyu Beck LEE ; Yun Kyu OH ; Hyeong Cheon PARK ; Seung Hyeok HAN ; Tae Hyun YOO ; Yeong Hoon KIM ; Soo Wan KIM ; Kang Wook LEE ; Hayne Cho PARK ; Sung Gyun KIM ; Hyunsuk KIM ; Chang Hwa LEE ; Kyongtae T. BAE ; Kook Hwan OH ; Curie AHN ; Hyun Jin RYU ; Yong Chul KIM
Kidney Research and Clinical Practice 2023;42(2):216-228
Tolvaptan reduces height-adjusted total kidney volume (htTKV) and renal function decline in autosomal dominant polycystic kidney disease (ADPKD). This study was aimed at investigating the efficacy and safety of tolvaptan in Korean patients with ADPKD during the titration period. Methods: This study is a multicenter, single-arm, open-label phase 4 study. We enrolled 108 patients with ADPKD (age, 19–50 years) with an estimated glomerular filtration rate (eGFR) of >30 mL/min/1.73 m2 and factors defined as indicative of rapid disease progression. After tolvaptan titration, we evaluated efficacy and side effects and assessed factors associated with the effects. Results: After titration for 4 weeks, eGFR and htTKV decreased by 6.4 ± 7.9 mL/min/1.73 m2 and 16 ± 45 mL/m, respectively. No serious adverse drug reactions were observed during the titration period. The greatest eGFR decline was observed in the first week, with a starting tolvaptan dose of 45 mg. Multivariate linear regression for htTKV decline showed that the greater the change in urine osmolality (Uosm), the greater the decrease in htTKV (β, 0.436; p = 0.009) in the 1D group stratified by the Mayo Clinic image classification. Higher baseline eGFR was related to a higher htTKV reduction rate in the 1E group (β, –0.642; p = 0.009). Conclusion: We observed short-term effects and safety during the tolvaptan titration period. The decline of htTKV can be predicted as a short-term effect of tolvaptan by observing Uosm changes from baseline to end of titration in 1D and baseline eGFR in 1E groups.
8.Wall shear stress on vascular smooth muscle cells exerts angiogenic effects on extracranial arteriovenous malformations
Jeong Yeop RYU ; Tae Hyun PARK ; Joon Seok LEE ; Eun Jung OH ; Hyun Mi KIM ; Seok-Jong LEE ; Jongmin LEE ; Sang Yub LEE ; Seung HUH ; Ji Yoon KIM ; Saewon IM ; Ho Yun CHUNG
Archives of Plastic Surgery 2022;49(1):115-120
Background:
In addition to vascular endothelial cells, vascular smooth muscle cells (VSMCs) are subject to continuous shear stress because of blood circulation. The angiogenic properties of VSMCs in extracranial arteriovenous malformations (AVMs) may exceed those of normal blood vessels if the body responds more sensitively to mechanical stimuli. This study was performed to investigate the hypothesis that rapid angiogenesis may be achieved by mechanical shear stress.
Methods:
VSMCs were obtained from six patients who had AVMs and six normal controls. The target genes were set to angiopoietin-2 (AGP2), aquaporin-1 (AQP1), and transforming growth factor-beta receptor 1 (TGFBR1). Reverse-transcriptase polymerase chain reaction (RT-PCR) and real-time PCR were implemented to identify the expression levels for target genes. Immunofluorescence was also conducted.
Results:
Under the shear stress condition, mean relative quantity values of AGP2, AQP1, and TGFBR1 in AVM tissues were 1.927±0.528, 1.291±0.031, and 2.284±1.461 when compared with neutral conditions. The expression levels of all three genes in AVMs were higher than those in normal tissue except for AQP1 under shear stress conditions. Immunofluorescence also revealed increased staining of shear stress-induced genes in the normal tissue and in AVM tissue.
Conclusions
Shear stress made the VSMCs of AVMs more sensitive. Although the pathogenesis of AVMs remains unclear, our study showed that biomechanical stimulation imposed by shear stress may aggravate angiogenesis in AVMs.
9.3D printed interim immediate denture by using the occlusal plane digital transfer method of the POP BOW system in a patient planning to extract upper and lower residual teeth: a case report
Do-Hyun PARK ; Eun-Bin BAE ; In-Hwan JUNG ; Chang-Mo JEONG ; Mi-Jung YUN ; Jung-Bo HUH ; So-Hyoun LEE
Journal of Dental Rehabilitation and Applied Science 2022;38(3):178-188
Interim immediate denture is fabricated to minimize the period of edentulousness after removal of the patient’s remaining teeth and before delivery of final prosthesis. In the case of using the CAD/CAM system, there is an advantage in that the manufacturing process in the clinic and laboratory can be simplified by overcoming some of the limitations of manufacturing interim immediate dentures in the traditional way. However, there are also disadvantages in that errors occur in the process of transmitting information about the patient’s intermaxillary relationship to the digital network of the laboratory, resulting in unstable occlusal relationships or non-esthetic prostheses. To overcome this problem, using the simple and accurate POP BOW system’s occlusal plane digital transfer method, it was possible to fabricate an esthetic and functional 3D printed interim immediate denture after removal of the remaining upper and lower anterior teeth.
10.National Follow-up Survey of Preventable Trauma Death Rate in Korea
Junsik KWON ; Myeonggyun LEE ; Jonghwan MOON ; Yo HUH ; Seoyoung SONG ; Sora KIM ; Seung Joon LEE ; Borami LIM ; Hyo Jin KIM ; Yoon KIM ; Hyung il KIM ; Jung-Ho YUN ; Byungchul YU ; Gil Jae LEE ; Jae Hun KIM ; Oh Hyun KIM ; Wook Jin CHOI ; Myungjae JUNG ; Kyoungwon JUNG
Journal of Korean Medical Science 2022;37(50):e349-
Background:
The preventable trauma death rate survey is a basic tool for the quality management of trauma treatment because it is a method that can intuitively evaluate the level of national trauma treatment. We conducted this study as a national biennial follow-up survey project and report the results of the review of the 2019 trauma death data in Korea.
Methods:
From January 1, 2019 to December 31, 2019, of a total of 8,482 trauma deaths throughout the country, 1,692 were sampled from 279 emergency medical institutions in Korea. All cases were evaluated for preventability of death and opportunities for improvement using a multidisciplinary panel review approach.
Results:
The preventable trauma death rate was estimated to be 15.7%. Of these, 3.1% were judged definitive preventable deaths, and 12.7% were potentially preventable deaths. The odds ratio for preventable traumatic death was 2.56 times higher in transferred patients compared to that of patients who visited the final hospital directly. The group that died 1 hour after the accident had a statistically significantly higher probability of preventable death than that of the group that died within 1 hour after the accident.
Conclusion
The preventable trauma death rate for trauma deaths in 2019 was 15.7%, which was 4.2%p lower than that in 2017. To improve the quality of trauma treatment, the transfer of severe trauma patients to trauma centers should be more focused.

Result Analysis
Print
Save
E-mail